(Q37000723)

17 August 2017

1 reference

title

Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline? (English)

1 reference

17 August 2017

0 references

1 reference

Sheila A Doggrell

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

17

1 reference

17 August 2017

page(s)

2903-2915

1 reference

The neurobiological bases for the pharmacotherapy of nicotine addiction

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Weight change among participants in a large sample minimal contact smoking relapse prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo‐controlled trial of nicotine gum with 2‐year follow‐up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Efficacy of a nicotine lozenge for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Randomised controlled trial of nasal nicotine spray in smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: A minimal intervention, randomized multicenter trial in a nonspecialized setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

A prospective study of off-label use of, abuse of, and dependence on nicotine inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

A comparison of a nicotine sublingual tablet and placebo for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Randomized Comparative Trial of Nicotine Polacrilex, a Transdermal Patch, Nasal Spray, and an Inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Comparison of three nicotine treatments: initial reactions and preferences with guided use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Smoking cessation in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

How does bupropion work as a smoking cessation aid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Bupropion for smoking cessation : predictors of successful outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Effects of gender on relapse prevention in smokers treated with bupropion SR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

The effect of bupropion sustained-release on cigarette craving after smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Targeting smokers at increased risk for relapse: treating women and those with a history of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Bupropion for smoking cessation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

The prevalence of weight concerns in a smoking abstinence clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Efficacy of bupropion in the indigenous Maori population in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

A double-blind study evaluating the long-term safety of varenicline for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

Effectiveness of smoking cessation therapies: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2903

10.1517/14656566.8.17.2903

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference